Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
Auditor change
Employment agrmnt
Oncotelic Therapeutics, Inc. (MATN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/23/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Sapu BioScience and Cromos Pharma initiating P201 – A Registrational trial for OT-101 in Pancreatic Cancer"
07/13/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "SUBSCRIPTION AGREEMENT AND INVESTMENT LETTER",
"ONCOTELIC THERAPEUTICS, INC. COMMON STOCK PURCHASE WARRANT ________, 2023 THIS COMMON STOCK PURCHASE WARRANT of Oncotelic Therapeutics, Inc., a corporation duly organized and validly existing under the laws of Delaware , is issued to the Holder as part of a unit purchased by the Holder from the Company pursuant to which the Holder is also purchasing from the Company notes convertible into shares of its Common Stock, $0.01 par value per share warrants to purchase 250,000 Common Stock . FOR VALUE RECEIVED, the Company hereby certifies that the registered holder hereof, [●], with an address at [●], and the Holder’ s successors and assigns , is entitled to purchase from the Company [●] duly authorized, validly issued, fully paid and nonassessable shares of Common Stock, at a ...",
"Cover Page Interactive Data File (embedded within the Inline XBRL document)",
"REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement is made and entered into as of __________, 2023, by and among Oncotelic Therapeutics, Inc. , a Delaware corporation with offices at 29397 Agoura Road, Suite 107, Agoura Hills, California 91301, and the investors signatories hereto . This Agreement is made pursuant to the Subscription Agreement and Investment Letter, dated as of the date hereof, executed by each of the Purchasers and the Company . NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and the Purchasers agree as follows: 1. Definitio ns. Capitalized terms used and not otherwise defined herein that are defined in th..."
05/19/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "OF ONCOTELIC THERAPEUTICS, INC. a Delaware Corporation"
03/13/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "High Intra-Tumor TGF-β2 Predicts Poor Survival in Pediatric Cancer of the Brainstem -The TGFβ1 and TGFβ3 isoforms are predictive —Validation of TGFβ2 as therapeutic target"
03/02/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/03/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "– JV continues to advance to its IPO - OT-101 immunotherapy expanding with at least 10 planned IIS clinical trials for 2023 - OT-101 commercialization effort expanding on multiple fronts - Manufacturing and DAO capabilities being built with platform launched slated for 2023 AGOURA HILLS, Calif., Dec. 28, 2022 – Oncotelic Therapeutics, Inc , a clinical stage cancer and aging biotechnology company, today issued a letter to its shareholders from its Chief Executive Officer, Dr. Vuong Trieu. To our Shareholders, 2022 was a defining year for Oncotelic as we entered into a JV agreement with Dragon Overseas Limited to form GMP Biosciences Limited to advance the development of OT-101 along multiple oncology indications through various pivotal internal studies and external investigator-initiated st..."
12/20/2022 8-K Quarterly results
07/15/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
06/22/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
04/13/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Letter to Oncotelic Shareholders on the Recently Completed Joint Venture Transaction with Dragon Overseas Capital Limited AGOURA HILLS, Calif., April 7th , 2022 – Oncotelic Therapeutics, Inc. , issued the following shareholder letter today."
04/06/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Oncotelic and Dragon Overseas Capital Limited Completed Joint Venture Transaction"
04/04/2022 8-K Entered into an underwriting agreement for the issuance and sale of notes
04/01/2022 8-K Investor presentation
02/17/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
02/15/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
02/09/2022 8-K Quarterly results
02/02/2022 8-K Entered into an underwriting agreement for the issuance and sale of notes
Docs: "Schedule 3.2 Disbursements",
"Schedule A Notice of Conversion"
01/28/2022 8-K Investor presentation
12/23/2021 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
12/15/2021 8-K Quarterly results
12/01/2021 8-K Entered into an underwriting agreement for the issuance and sale of notes
Docs: "SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT , dated as of November 24, 2021, by and between ONCOTELIC THERAPEUTICS, INC., a Delaware corporation, with headquarters located at 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301 , and _______________________, a ___________________________________________, with its address at _____________________________ . WHEREAS: A. The Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4 of the Securities Act of 1933, as amended and Rule 506 promulgated by the United States Securities and Exchange Commission under the 1933 Act; B. Buyer desires to purchase from the Company, and the Company desires to issue and sell to the Buyer, upon the te...",
"PROMISSORY NOTE FOR VALUE RECEIVED, ONCOTELIC THERAPEUTICS, INC., a Delaware corporation , hereby promises to pay to the order of _______________________________, a _________________, or registered assigns , in the form of lawful money of the United States of America, the principal sum of $_________________, which amount is the $__________ actual amount of the purchase price hereof plus an original issue discount in the amount of $__________ and to pay interest on the unpaid Principal Amount hereof at the rate of twelve percent per annum shall be guaranteed and earned in full as of the Issue Date) from the date hereof until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment or otherwise, as further provided herein. The maturity date shall be twelv..."
11/24/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "AGOURA HILLS, Calif., November, 23 2021 - Oncotelic Therapeutics, Inc. , a leading developer of TGF-β therapeutics for oncology and virology, today announced that its COVID-19 trial for OT-101 has successfully met its safety and efficacy endpoints."
11/16/2021 8-K Regulation FD Disclosure  Interactive Data
Docs: "Oncotelic Announces Successful Completion of the Safety Evaluation of a TGF-β Inhibitor and IL-2 in Phase 1 Combination Trial in Solid Tumor Cancers"
10/28/2021 8-K Entered into an underwriting agreement for the issuance and sale of notes
Docs: "Schedule 3.2 Disbursements",
"Schedule A Notice of Conversion"
10/04/2021 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "LICENSE AGREEMENT BETWEEN ONCOTELIC THERAPEUTICS, INC. AND AUTOTELIC INC.",
"Oncotelic Acquires FAST TO MARKET LATE-STAGE drug candidate for Parkinson Disease, Erectile Dysfunction, and Female Sexual Dysfunction."
09/27/2021 8-K Entered into an underwriting agreement for the issuance and sale of notes
Docs: "Schedule 3.2 Disbursements",
"Schedule A Notice of Conversion"
09/08/2021 8-K Investor presentation
09/03/2021 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "STRICTLY CONFIDENTIAL Oncotelic Therapeutics, Inc and Autotelic Inc. Term Sheet The following term sheet sets forth a summary of the basic terms of a contemplated licensing transaction , wherein Oncotelic, a Delaware Corporation with its shares traded on OTCQB and Autotelic, a California Corporation, would enter into a licensing transaction, with an anticipated closing date no later than the 4th quarter of 2021. This Term Sheet is binding on the parties and shall survive termination as defined."
08/26/2021 8-K Investor presentation
Docs: "IS CLINICALLY ACTIVE AGAINST MILD AND MODERATE"
08/17/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "GMP and Oncotelic forming JV for IPO"
08/05/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Form of Convertible Promissory Note, issued by the Company under the Note Purchase Agreement",
"Form of Note Purchase Agreement, by and among the Company and the investors identified therein"
07/19/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy